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Abstract
The development of a biosensor system capable of continuous, real-time measurement of small-
molecule analytes directly in complex, unprocessed aqueous samples has been a significant
challenge, and successful implementation has been achieved for only a limited number of targets.
Towards a general solution to this problem, we report here the Microfluidic Electrochemical
Aptamer-based Sensor (MECAS) chip wherein we integrate target-specific DNA aptamers that fold,
and thus generate an electrochemical signal, in response to the analyte with a microfluidic detection
system. As a model, we demonstrate the continuous, real-time (~1 minute time resolution) detection
of the small molecule drug cocaine at near physiological, low micromolar concentrations directly in
undiluted, otherwise unmodified blood serum. We believe our approach of integrating folding-based
electrochemical sensors with miniaturized detection systems may lay the ground work for the real-
time, point-of-care detection of a wide variety of molecular targets.
The capability to perform in situ, continuous, real-time monitoring of specific small molecules
in complex, unprocessed aqueous samples is important for a broad spectrum of applications
ranging from medical diagnostics to environmental monitoring.1 However, successful
implementation of such strategies has proven elusive, and thus far has been achieved for only
a few, specialized targets (e.g., neurotransmitters, such as 5-hydroxytryptamine,2 hydrogen
ions3 and glucose4). The challenge of real-time sensing arises from the fact that, to meet this
demanding application, a sensor needs not only be sensitive, stable and selective enough to
deploy directly in complex sample matrices, but it also needs to be reagentless, regenerable
and able to respond rapidly relative to the timescale with which the target concentration
fluctuates.
Previously-developed strategies for the real-time detection of small-molecule analytes have
typically made use of sensors that measure changes in mass,5 index of refraction6 or charge7
that occur when the target molecules bind to the sensor surface. Such measurements, however,
suffer from often severe false positives; for example, it has proven difficult to discriminate
between changes in mass arising from the binding of authentic target molecules and those
*To whom all correspondence should be addressed. Tel. No. 1-805-893-8737, Fax No. 1-805-893-8651, E-mail: E-mail:
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arising due to the non-specific adsorption of contaminants, which has significantly hindered
the application of these adsorption-based sensors in complex samples, such as unprocessed
clinical or environmental materials.5–7 In contrast, sensors based on binding-induced
conformational changes in a bimolecular probe8–9 have proven more effective in rejecting such
false positives. An example is the electrochemical, aptamer-based (E-AB) sensor platform,
which operates via the target binding-induced folding of DNA and RNA aptamers and has been
shown to work directly in blood serum,10–12 crude cellular extracts,13 soil extracts14 and
foodstuffs.15 The high selectivity of E-AB sensors is attributed to two effects. First, in this
architecture, the non-specific binding of interferants does not trigger a conformational change
in the aptamer, due to lack of molecular recognition. Second, the target binding-induced
conformational change is signaled electrochemically, and electroactive contaminants within
the potential range of the employed redox tags are rare. These advantages, in combination with
the stability of DNA probes and reagentless, regenerable characteristics of the platform, suggest
that it is well suited for real-time operation.
In addition to requiring a rapidly equilibrating sensing element, the continuous, real-time
detection of aqueous analytes also requires that we overcome the limitations imposed by
diffusion and mass transport in bringing the target molecules to the sensor surface. Here, due
to the fact that microfabrication allows precise patterning of multiple electrodes in miniaturized
flow cells, microfluidics technology offers important advantages on mass transport and
diffusion over conventional macro-scale devices. In this work, we report the development of
the Microfluidic Electrochemical Aptamer-based Sensor (MECAS) chip, wherein we integrate
an E-AB sensor within a miniaturized electrochemical cell, to achieve continuous, real-time
monitoring of cocaine in undiluted, unmodified blood serum at physiologically-relevant
concentrations and with physiologically-relevant time resolution.
EXPERIMENTAL SECTION
Materials
Tris-(2-carboxyethyl) phosphine hydrochloride (TCEP), cocaine, 6-mercaptohexanol, Saline-
sodium citrate (SSC) buffer (20× concentrate, 0.3 M sodium citrate, pH 7.0, containing 3 M
NaCl) and fetal calf serum (from formula-fed bovine calves, sterile-filtered, cell culture tested,
iron-supplemented) were purchased from Sigma-Aldrich, Inc. (St. Louis, MO) and used as
received without further purification. Our thiolated, methylene blue (MB)-labeled DNA
aptamer probe was synthesized and purified by Biosearch Technologies, Inc. (Novato, CA).
The sequence of the modified cocaine binding aptamer is: 5’-HS-(CH2)11-
AGACAAGGAAAATCCTTCAATGAAGTGGGTCG-(CH2)7-MB-3’. As reported, the
selectivity of the cocaine aptamer for cocaine over its metabolites (for example, benzoyl
ecgonine and ecgonine methyl ester) is high.16
MECAS chip Fabrication
Four-inch-diameter Borofloat glass wafers with a thickness of 500 µm (Precision Glass &
Optics, Santa Ana, CA) were used as the substrate for the MECAS chip. The chip incorporates
a 750-nl detection chamber containing three gold working electrodes, a platinum reference
electrode and a platinum counter electrode patterned using standard microfabrication
processes.
The MECAS fabrication architecture is modular in design (Fig. 1) consisting of three processes:
(a) fabrication of the electrode substrate, (b) fabrication of the chamber substrate, and (c)
assembly of the two substrates to yield a completed device (d). The electrode substrate (Fig.
1a) incorporated platinum counter and electrodes (size: 3200 µm2, 1300 µm2) which were
patterned via optical photolithography. An electron beam evaporator was used to deposit a 20
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Å Ti glass-adhesion layer and then 2500 Å of platinum. Gold working electrodes (three
electrodes each at 800 µm2) were aligned and patterned with respect to the existing platinum
electrodes and 2500 Å Au on 20 Å Ti layers were deposited using the same deposition method.
We fabricated three working gold electrodes on the MECAS chip because this design allows
the simultaneous collection of three sets of data at the same concentrations of cocaine in order
to calculate the standard derivation of sensor response.
The chamber substrate (Fig. 1b) was processed in a second glass wafer. An amorphous silicon
(α-Si) sacrificial etch mask was fist sputtered onto the glass wafer (2500 Å). In order to define
the chamber area, vias were patterned and developed in the photoresist, exposing the underlying
amorphous silicon layer on the surface of the glass wafer. The exposed amorphous silicon was
completely etched down to the underlying glass surface using a reactive ion CF4 plasma etch.
Borofloat glass was exposed only where the chamber is to be etched into the wafer. Next, the
chamber was isotropically etched for 7 minutes in 45% hydrofluoric acid to ~35 µm depth.
Any residual photoresist was washed in acetone, isopropyl alcohol and distilled, deionized
water (DI water). The remaining α-Si was etched away in CF4 plasma again, leaving only glass.
Finally, 0.75 mm inlet and outlet holes were drilled through the chamber wafer with a
computerized mill for precision placement.
The MECAS chip was assembled as follows (Fig. 1c). The electrode wafer and the chamber
wafer were diced to the desired dimensions to create glass chips which were then cleaned by
sonication in acetone and isopropanol and rinsing in DI water. Following this step the chips
were soaked face-up in a piranha cleaning solution for 10 minutes before being rinsed
thoroughly in DI water and dried under nitrogen flow. The cleaned chips were then brought
together, aligned, and sandwiched between two graphite blocks for glass fusion bonding in a
furnace. A 2 kg mass was rested on the top graphite block, applying a constant pressure of
approximately 3 kPa to the aligned chip. Under constant nitrogen flow, the furnace temperature
was raised from room temperature to 590 °C at a rate of 10 °C/minute and held for 3 hours.
The furnace was then allowed to cool passively back to room temperature. Upon removal from
the furnace, the two chips were fused into a completed MECAS chip with a microfluidic
channel defining fluid delivery to the patterned gold and platinum electrodes. Eyelets made of
Tygon tubing were aligned and glued to the inlet and outlet holes of the MECAS chip to allow
for fluid delivery into the chip (Fig. 1d).
Immobilization of the Aptamer probe
In order to clean the gold working electrodes prior to immobilization of the thiolated, MB-
modified, cocaine-binding aptamer we performed a series of oxidation and reduction cycles in
0.5 M H2SO4, 0.01 M KCl/0.1 M H2SO4, and 0.05 M H2SO4 (Fig. 2a).17 The chamber was
then immediately filled with 1.0 µM aptamer probe solution. To prepare this solution, a 0.2
mM aptamer in 10 mM Tris solution was first reduced with 5 mM TCEP for 1 hr to cleave
disulfide bonds and then diluted to 1.0 µM with phosphate buffer (0.1 M sodium phosphate,
1.5 M NaCl, 1 mM MgCl2, pH 7.4) for 1 hr, all at room temperature. After probe
immobilization, the chamber was rinsed with DI water and then filled with a freshly-prepared
solution of 2 mM 6-mercaptohexanol for 4 hr to passivate the remaining bare electrode area
and displace physically adsorbed DNA.18 The chamber was then rinsed again with DI water
and filled with 1× SSC buffer (15 mM sodium citrate, 150 mM NaCl, pH 7.0) prior to
measurements. This process yielded highly robust and stable sensors that can operate in blood
serum for > 1 hour (Supporting information, Fig S1). Previous work19 suggests that that the
stability of C11-based sensors is significantly improved relative to that of C6-based sensors,
suggestion that the use of C11-chain aptamer would result in more stable SAMs and longer
sensor shelf life in serum.
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Characterization of the aptamer probe on the sensor chip
The immobilization of the aptamer probe was verified in 1× SSC buffer solution with a platinum
counter electrode and a platinum reference electrode in the detection chamber via reduction
scans on a CHI 730B potentiostat (CH Instruments, Austin, TX). Alternating current
voltammograms (ACV) were acquired in the buffer using a 25 mV amplitude signal at 10 Hz
over a potential window of −0.25 V to −0.65 V. The aptamer probe density was measured using
ACV;20 optimal probe densities (which, as reported by this measure, are in the range of 20 ±
3 pmol·cm−2 -data not shown) were employed throughout this study. Some chip-to-chip
variations in the baseline currents were found. We attribute this phenomenon to differences in
the surface area of the electrodes caused by inaccuracies in device fabrication, deviations in
the surface coverage of the modified aptamers on the electrodes, and minor changes in the
resistances of the leads and connections. In particular, we found that the surface coverage of
the aptamers was highly dependent on the surface roughness of the deposited gold film. Thus,
relative sensor response (%), rather than the absolute values of the current, is employed in the
calibration curve.
Real-time detection of cocaine in continuously flowing serum
For real-time cocaine detection, four samples of undiluted, otherwise unmodified fetal bovine
serum were prepared in separate syringes, each doped with different concentrations of cocaine
(0 µM, 10 µM, 50 µM, and 100 µM). The syringes were connected to a four-input, single-
output multiplexed valve (Cole-Parmer, Vernon Hills, IL) via Tygon tubing such that only one
sample can be selected to enter the MECAS chip at a time (Fig. 2 a,b). Each selected sample
was pumped through the chip at a constant flow rate of 600 µl/hr. Trial studies using a
fluorescent dye indicate a sample chamber can be filled in 4.5 seconds (166 nl/s) (data not
shown). Using this setup, the concentration of cocaine in the serum within the chip was
modulated from 0 µM to 10 µM to 50 µM to 0 µM to 100 µM to 0 µM in a continuous manner.
At each concentration, ACV measurements were performed every 27 seconds scanning from
−0.25 V to −0.65 V, and the peak reduction current is recorded using a computer controlled
data acquisition system.
RESULTS AND DISCUSSION
The MECAS chip incorporates three gold working electrodes, a platinum reference electrode
and a platinum counter electrode within a 750-nl detection chamber. The working electrodes
are functionalized with a 32-base cocaine-binding aptamer12 that is partially unfolded in the
absence of its target molecule (Fig. 2c, left). The aptamer probe is modified with the redoxable
methylene blue (MB) moiety at its 3’ terminus, and is attached to the gold working electrode
at its 5’ terminus via gold-thiol linkage.21 Upon target binding, the aptamer folds to its folded,
cocaine-binding conformation, increasing the efficiency with which electrons are transferred
from the MB tag to the electrode, thereby producing a readily measurable increase in faradaic
current (Fig. 2c, right).
The MECAS chip responds sensitively and selectively to its target analyte. As an initial test
of this we performed static measurements of the response of the aptamer-based sensor
contained within. In doing so, we found that the chip rapidly responds to micromolar
concentrations of cocaine in undiluted, unmodified blood serum: when challenged with 250
µM cocaine doped in serum the faradaic current increases by ~38% relative to the current
observed in the absence of target (Fig. 3). Upon a brief wash with serum lacking cocaine, the
sensor is readily regenerated, with the signal returning to 97% of its initial value (Fig. 3). Sensor
regeneration allows for the MECAS sensor reuse at 10 µM cocaine for more than three times
in undiluted blood serum with a mean recovery of > 96% of the original signal before significant
degradation is observed (Supporting information, Fig. S1).
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In order to measure the sensor’s response to continuously flowing serum containing cocaine
at physiological concentrations,22 we employed a multi-port valve to deliver four different
serum samples doped with varying levels of cocaine and measured the associated faradaic
currents from the MECAS chip. We find that the chip responds selectively and rapidly to
varying target cocaine concentrations with a signal effectively indistinguishable from that
observed with static samples (Fig. 4, left). For example, a stream of undiluted, cocaine-free
serum produced a relatively flat, low-current baseline, as would be expected for the sensor in
the absence of target. When sample containing 10 µM cocaine is introduced into the chip the
faradaic current increases by 6%. Further increases in the concentration of cocaine produce
progressively larger increases in faradaic current, with a gain of 26% observed at the highest
concentration used in this experiment (100 µM). The observed signal exhibits the hyperbolic
“dose-response” curve expected for single-site binding, with an estimated dissociation constant
of 100±9 µM (Fig. 4, right). This dissociation constant is effectively identical to that reported
for the sensing aptamer in solution,16 suggesting that the binding affinity of the aptamer is not
affected by its immobilization within the microfluidic device or by the collection of
measurements in a continuously-flowing sample stream. Furthermore, we also performed
titration experiments in which the direction of the cocaine concentration gradient was reversed
(i.e. from high to low concentrations) (Supporting information, Fig. S2). The performance of
the sensor did not depend on the direction of the gradient, and the observed sensor signals were
almost identical to those reported in Figure 4.
The MECAS chip exhibits excellent baseline stability in continuously-flowing serum: the
signaling current of the device rapidly returns to baseline values when the flow of cocaine-
doped serum is replaced with cocaine-free serum (Fig. 4, left). This occurs even after 60
minutes of exposure to flowing serum, which is equivalent to approximately 800 flow-cell
volumes, and occurs despite the numerous nucleases contained in serum that might be expected
to degrade the sensing aptamer. The apparent stability of the sensing aptamer may be a result
of its surface immobilization and MB modification;23 we have previously shown that a similar
electrochemical DNA-based sensor can be stored in blood serum for more than a week at room
temperature without exhibiting substantial degradation.19 It also appears that physical
adsorption of background serum protein to the hydroxyl-coated SAM passivation layer does
not affect target access to or folding of the aptamer probe during the 60 minutes of exposure.
We note, however, that longer exposure times (3+ hours) under continuously flowing serum
lead to some signal loss (data not shown), presumably due to the non-specific protein deposition
from serum onto the sensor surface. Consistent with this, under these conditions we find that
flushing the chamber with a protein denaturing solution (6M Guanadine HCl) recovers nearly
the entire original peak signal (9.7% signal loss; data not shown). For continuous, in situ, real-
time measurements in aqueous analyte, it is important to overcome the limitations imposed by
mass transport of the target to the sensor surface. Here microfluidic technology provides an
important advantage; because the sample stream is flowing at a rate that fills the entire chamber
in just 4.5 seconds (166 nl/s), in comparison to macro-scale counterparts, the miniaturized
detection chamber readily allows continuous delivery of the analyte to the sensor surface.
Consistent with this feature, the sensor exhibits concentration-dependent rise-times of 1 to 2
minutes (and, because we are operating near the dissociation constant of the aptamer, similarly
rapid fall times), which compares favorably with the minutes-to-hours physiological timescale
of the uptake, action and metabolism of the drug.24 For example, with insufflation, the onset
of cocaine’s action occurs 1–3 minutes after use, peaks 20–30 minutes later and lasts 45–90
minutes overall. Likewise the serum half-life of the drug is typically 60 to 90 minutes.25
In summary, we report here an analytical strategy that combines electrochemical, aptamer-
based sensing with miniaturized, microfluidic sample handling technology to perform
continuous, real-time detection of a small molecule analyte directly in a complex, flowing
sample matrix. To apply our approach to other molecular targets, aptamers that undergo target
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binding-induced folding are necessary. Toward this end, a number of such aptamers has already
been reported against a wide range of molecular targets,26 and innovative screening methods
have been developed to directly isolate such structure-changing aptamer molecules.27–28
Importantly, general methodologies to incorporate the binding-induced folding feature into
existing aptamers have also been described.29 Given this, it may be possible to extend our
approach beyond small-molecule drugs to a range of other analytes for convenient, quantitative,
real-time detection at the point-of-care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The microfabrication process flow of the MECAS chip is modular, allowing independent
processing of (a) the electrode and (b) the chamber substrates. The two substrates are then
fusion bonded to form a monolithic device (c). The electrode substrate contains microfabricated
platinum reference (R) and counter (C) electrodes in additions to three independent gold
working (sensing) electrodes (W1,W2,W3). (d) A photo of the completed MECAS chip.
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Figure 2.
Shown schematically is experimental setup for real time cocaine detection in continuously-
flowing, undiluted blood serum. (a): The microfabricated MECAS chip contains a 750-nl
detection chamber with integrated electrodes. (b): The syringe pumps are connected to a four-
input, single-output multiplexed valve via Tygon tubing such that only one sample enters the
chip at a time. (c): The detection mechanism of the folding-based E-AB sensor.
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Figure 3.
The MECAS chip readily detects cocaine in undiluted, unmodified blood serum. Shown are
alternating current (AC) voltammograms collected using the MECAS chip filled with 250 µM
of cocaine in static, undiluted serum. Regeneration of 97% was obtained after challenging with
a target-free serum.
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Figure 4.
The MECAS device supports the real-time monitoring of cocaine at micromolar concentrations
in continuously flowing, undiluted, unmodified blood serum. (Left) Real-time detection of
cocaine in flowing serum, with the concentration modulated over the course of the experiment
as denoted. (Right) A calibration curve derived for various concentrations of cocaine in
undiluted serum (monitored in real-time in continuously-flowing serum) indicates that the
cocaine dissociation constant measured in the chip is effectively indistinguishable from
reported values in solution.21
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